VIDEO: Ongoing research in T-cell therapies for AML

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Currently there are no approved CAR T therapies for the treatment of patients with relapsed and refractory AML or myeloid malignancies. And we think that that is in part because of our inability to determine which would be the best antigen for our CAR T cells to target in this particular disease type.

There are ongoing studies that have looked at CD33, NKG2, CD123, newer antigens such as CLL1, WT1, and potentially novel antigens. But we have yet to see in our portfolio a successful CAR T therapy. That being said, many investigators are pursuing not only autologous but also allogeneic CAR T therapy, off the shelf entities. Where we're collecting healthy T cells from normal donors and using that as a method to more rapidly bring CAR T cells into our patients, given the fact that our patients have rapidly progressive disease. We're also looking at alternative adoptive T-cell approaches. Could we use, instead of CD3-positive T-cells? Could we use gamma delta T cells? Could we be looking at natural killer cells as a another method? Could we be using macrophages as another source? So, I think that the investigation and research into adoptive T-cell therapy, or other adoptive cell transfer, for patients with myeloid malignancy still remains a hot topic and is still open to debate and ongoing research.